UPDATE: Wedbush Upgrades Oncothyreon on Statistically Significant Overall Survival Benefit
May 17, 2013 at 13:45 PM EDT
In a report published on Friday, Wedbush analyst Gregory Wade upgraded Oncothyreon (NASDAQ: ONTY ) from Neutral to Outperform and raised the price target from $2.00 to $5.00. In the report, Wedbush noted, "Merck KGaA(Merck Serono) reported new analysis of the Phase III data from the completed L-BLP25 (STIMUVAX) non-small
